Composition, form of production and packaging
? Tablets for resorption of white or almost white color, flat-cylindrical, with a smooth shiny surface, with bevelled edges, with a mint smell, slight marble is allowed.
1 tab.
a mixture of bacterial lysates (ImudonВ®) (in terms of dry matter) 2.7 mg,
in t.ch. Lysates of bacteria Lactobacillus acidophilus, Lactobacillus delbrueckii ss lactis, Lactobacillus helveticus, Lactobacillus fermentum, Streptococcus pyogenes groupe A, Streptococcus sangius groupe H, Staphylococcus aureus, Enterococcus faecium, Enterococcus faecalis, Klebsiella pneumoniae ss pneumoniae, Fusobacterium nucleatum ss fusiforme, Corynebacterium pseudodiphtheriticum, Candida albicans 0.1575 mg
auxiliary substances: glycine - 2 mg, sodium deoxycholate - 0.53 mg, thiomersal - not more than 0.0125 mg
Auxiliary substances: glycine - 47.3 mg, lactose monohydrate 350 mg, mannitol 100 mg, sodium saccharinate 1.12 mg, povidone 10 mg, sodium hydrogen carbonate 30 mg, citric acid anhydrous 23 mg, peppermint flavor 8 mg, magnesium stearate - 4.88 mg.
8 pcs. - packings cellular planimetric (3) - packs cardboard.
8 pcs. - packings cellular planimetric (5) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2015.
PHARMACHOLOGIC EFFECT
Immunostimulating drug of bacterial origin for topical application in otorhinolaryngology, dentistry. It is a multivalent antigenic complex, a mixture of bacterial lysates, whose composition corresponds to the pathogens most often causing inflammatory processes in the oral cavity and pharynx.
Imudon В® activates phagocytosis, promotes an increase in the number of immunocompetent cells, increases the production of lysozyme and interferon, and immunoglobulin A in saliva.
PHARMACOKINETICS
There is no information in this manual.
INDICATIONS
Treatment and / or prevention of inflammatory and infectious diseases of the oral cavity and pharynx:
pharyngitis;
- chronic tonsillitis;
- preoperative preparation and postoperative period after tonsillectomy;
- superficial and deep periodontosis, periodontitis, stomatitis (including aphthous), glossitis;
erythematous and ulcerative gingivitis;
- Dysbacteriosis of the oral cavity;
- infection after tooth extraction, implantation of artificial dental roots;
- ulceration caused by dentures.
DOSING MODE
Adults and adolescents older than 14 years with acute inflammatory diseases of the oral cavity and pharynx and exacerbation of chronic diseases the drug is prescribed in a dose of 8 tablets / day. Tablets dissolve (not chewing) in the oral cavity with an interval of 1-2 hours. The average duration of the course of treatment is 10 days.
To prevent exacerbation of chronic inflammatory diseases of the oral cavity and pharynx, the drug is prescribed in a dose of 6 tablets / day. Tablets dissolve (not chewing) in the oral cavity with an interval of 2 hours. The duration of the course of treatment is 20 days.
It is recommended to conduct preventive courses 3-4 times a year.
Children aged 3 to 14 years in the treatment of acute and exacerbation of chronic inflammatory diseases of the oral cavity and pharynx drug prescribed in a dose of 6 tablets / day. Tablets dissolve (not chewing) in the oral cavity with an interval of 1-2 hours. Duration of treatment for acute diseases is 10 days, for prevention of exacerbation of chronic diseases - 20 days.
The course of preventive use is recommended to be repeated 3-4 times a year.
SIDE EFFECT
Allergic reactions: rarely - skin rash, hives, angioedema.
From the side of the digestive system: rarely - nausea, vomiting, abdominal pain.
From the respiratory system: rarely - exacerbation of bronchial asthma, cough.
Dermatological reactions: very rarely erythema nodosum.
From the coagulation system: very rarely - hemorrhagic vasculitis, trobocytopenia.
Other: rarely - fever.
CONTRAINDICATIONS
- autoimmune diseases;
- children's age till 3 years;
- increased individual sensitivity to the drug or its components.
PREGNANCY AND LACTATION
Information on the use of Imudon in pregnancy is not enough. Corresponding data on animal experiments and epidemiological studies are lacking.
It is not recommended to take Imudon В® during pregnancy and lactation (breast-feeding).
APPLICATION FOR CHILDREN
Children between the ages of 3 and 6 years must resolve the pill under the supervision of adults.
SPECIAL INSTRUCTIONS
Do not take food and water, and rinse your mouth for 1 hour after applying Imudon, so as not to reduce the therapeutic effectiveness of the drug.
When the drug is prescribed for patients who observe a salt-free or low-salt diet, it must be taken into account that 1 tab. Imudon contains 15 mg of sodium.
Patients with bronchial asthma who receive drugs containing bacterial lysates cause an exacerbation of the disease (attack of bronchial asthma), it is not recommended to use the drug.
Use in Pediatrics
Children aged 3 to 6 years must resolve the tablets under the mandatory supervision of adults.
Impact on the ability to drive vehicles and manage mechanisms
There is no evidence of the need for any restrictions on activities related to driving or other mechanisms during the treatment period.
OVERDOSE
The cases of an overdose of Imudon В® are not described.
DRUG INTERACTION
Drug interaction was not observed. Imudon В® can be used concomitantly with other medications.
TERMS OF RELEASE FROM PHARMACY
The drug is approved for use as a means of OTC.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored out of reach of children at a temperature of no higher than 25 В° C. Shelf life - 2 years. Store and transport the preparation in accordance with SP3.3.2.1248-03 at a temperature of no higher than 25 В° C.
